Vis enkel innførsel

dc.contributor.authorAglago, Elom K.
dc.contributor.authorRinaldi, Sabina
dc.contributor.authorFreisling, Heinz
dc.contributor.authorJiao, Li
dc.contributor.authorHughes, David J.
dc.contributor.authorFedirko, Veronika
dc.contributor.authorSchalkwijk, Casper C
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorDahm, Christina C.
dc.contributor.authorOvervad, Kim
dc.contributor.authorEriksen, Anne Kirstine
dc.contributor.authorKyrø, Cecilie
dc.contributor.authorBoutron-Ruault, Marie-Christine
dc.contributor.authorRothwell, Joseph A.
dc.contributor.authorSeveri, Gianluca
dc.contributor.authorKatzke, Verena
dc.contributor.authorKuhn, Tilman
dc.contributor.authorSchulze, Matthias B.
dc.contributor.authorKrasimira, Aleksandrova
dc.contributor.authorMasala, Giovanna
dc.contributor.authorKrogh, Vittorio
dc.contributor.authorPanico, Salavatore
dc.contributor.authorTumino, Rosario
dc.contributor.authorNaccarati, Alessio
dc.contributor.authorBueno-De-Mesquita, Bas
dc.contributor.authorvan Gils, Carla H.
dc.contributor.authorSandanger, Torkjel M
dc.contributor.authorGram, Inger Torhild
dc.contributor.authorSkeie, Guri
dc.contributor.authorQuiros, J. Ramon
dc.contributor.authorJakszyn, Rachel
dc.contributor.authorSanchez, Maria-Jose
dc.contributor.authorAmiano, Pilar
dc.contributor.authorHuerta, Jose Maria
dc.contributor.authorArdanaz, Eva
dc.contributor.authorJohansson, Ingegerd
dc.contributor.authorHarlid, Sophia
dc.contributor.authorPerez-Cornago, Aurora
dc.contributor.authorMayén, Ana-Lucia
dc.contributor.authorCordova, Reynalda
dc.contributor.authorGunter, Marc J.
dc.contributor.authorVineis, Paolo
dc.contributor.authorCross, Amanda J.
dc.contributor.authorRiboli, Elio
dc.contributor.authorJenab, Mazda
dc.date.accessioned2021-03-29T21:24:26Z
dc.date.available2021-03-29T21:24:26Z
dc.date.issued2020-10-20
dc.description.abstract<p>Background: Overexpression of the receptor for advanced glycation end-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation. <p>Methods: To investigate whether sRAGE and related genetic variants are associated with colorectal cancer risk, we conducted a nested case–control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 colorectal cancer matched case–control sets. Twenty-four SNPs encoded in the genes associated with sRAGE concentrations were available for 1,985 colorectal cancer cases and 2,220 controls. Multivariable adjusted ORs and 95% confidence intervals (CIs) were computed using conditional and unconditional logistic regression for colorectal cancer risk and circulating sRAGE and SNPs, respectively. <p>Results: Higher sRAGE concentrations were inversely associated with colorectal cancer (OR<sub>Q5vs.Q1</sub>, 0.77; 95% CI, 0.59–1.00). Sex-specific analyses revealed that the observed inverse risk association was restricted to men (OR<sub>Q5vs.Q1</sub>, 0.63; 95% CI, 0.42–0.94), whereas no association was observed in women (OR<sub>Q5vs.Q1</sub>, 1.00; 95% CI, 0.68–1.48; P<sub>heterogeneity</sub> for sex = 0.006). Participants carrying minor allele of rs653765 (promoter region of <i>ADAM10</i>) had lower colorectal cancer risk (C vs. T, OR, 0.90; 95% CI, 0.82–0.99). <p>Conclusions: Prediagnostic sRAGE concentrations were inversely associated with colorectal cancer risk in men, but not in women. An SNP located within <i>ADAM10</i> gene, pertaining to RAGE shedding, was associated with colorectal cancer risk. <p>Impact: Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in colorectal cancer development.en_US
dc.identifier.citationAglago, Rinaldi S, Freisling H, Jiao, Hughes DJ, Fedirko V, Schalkwijk, Weiderpass E, Dahm CC, Overvad K, Eriksen, Kyrø C, Boutron-Ruault M, Rothwell JA, Severi G, Katzke V, Kuhn T, Schulze MB, Krasimira A, Masala G, Krogh V, Panico S, Tumino R, Naccarati A, Bueno-De-Mesquita B, van Gils CH, Sandanger TM, Gram IT, Skeie G, Quiros JR, Jakszyn, Sanchez M, Amiano P, Huerta JM, Ardanaz E, Johansson I, Harlid S, Perez-Cornago A, Mayén, Cordova R, Gunter MJ, Vineis P, Cross AJ, Riboli E, Jenab M. Soluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a 1 case-control study nested within a European prospective cohort. Cancer Epidemiology, Biomarkers and Prevention. 2020en_US
dc.identifier.cristinIDFRIDAID 1886265
dc.identifier.doi10.1158/1055-9965.EPI-20-0855
dc.identifier.issn1055-9965
dc.identifier.issn1538-7755
dc.identifier.urihttps://hdl.handle.net/10037/20758
dc.language.isoengen_US
dc.publisherAmerican Association for Cancer Researchen_US
dc.relation.journalCancer Epidemiology, Biomarkers and Prevention
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.titleSoluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a 1 case-control study nested within a European prospective cohorten_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel